The company discontinued developing emugrobart after two studies showed the drug didn’t achieve intended outcomes.

Backed by partner Sanofi, Earendil will expand the utility of its AI-driven drug discovery platform, while progressing its ...

Chugai Pharmaceutical Co. fell 7.3%, the largest intraday decline since August 2025, after the company said it had ended the ...

Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of ...

Siren Biotechnology today announced that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application submitted by the University of California, San Francisco ...

Gilead Sciences said on Monday it would buy privately held biotech firm Ouro Medicines in a deal worth more than $2 billion ...

Ms. Jarrett brings nearly three decades of executive leadership in biotech, tech and finance -- -- Biotech leaders Dr. Cameron Turtle and Mike Landsittel appointed to Board of Directors -- -- Peter ...

California biotech Kali Therapeutics has snagged its first major pharma partner, Sanofi, which is committing $180 million in ...

Earendil Labs has raised an impressive $787 million in financing for its AI-powered drug discovery and development platform, ...

Persevere Therapeutics announced a $1.5 million raise earlier this month for its cancer treatment. Established life sciences company BioCurie also secured funding, a $9.3 million award from the ...

When Ron Cohen, M.D., CEO of Oryon Cell Therapies, recently dug into the company’s Parkinson’s disease data, he told Fierce ...

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug ...